BioCentury | Mar 25, 2019
Distillery Therapeutics

Inhibiting RAR for retinitis pigmentosa

DISEASE CATEGORY: Ophthalmic disease INDICATION: Retinitis Mouse studies suggest inhibiting RAR could help treat retinitis pigmentosa. In a mouse model of retinitis pigmentosa, intravitreal injection of a pan-RAR inverse agonist tool compound increased retinal sensitivity...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

INDICATION: Sarcoma In vitro , mouse and pig studies identified an RXR agonist that could help treat soft tissue sarcoma (STS). In silico screening of a small molecule library for compounds predicted to bind RXR, followed...
BioCentury | Nov 17, 2017
Clinical News

IRX reports Phase IIa data for citoplurikin in SCCHN

In September, IRX Therapeutics Inc. (New York, N.Y.) reported data from a Phase IIa trial in 27 patients with squamous cell carcinoma of the head and neck (SCCHN) showing that subcutaneous citoplurikin (IRX-2) reduced tumor...
BioCentury | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; cutaneous T cell lymphoma (CTCL) In vitro and cell culture studies identified agonists of RXR heterodimerization that could help treat colorectal cancer, CTCL and other cancers without causing the metabolic and...
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BioCentury | Feb 25, 2016
Strategy

Changing the channel

Having helped expose the reproducibility crisis about five years ago, Amgen Inc. is staying at the forefront of the issue with its support of F1000Research , an open-science platform to let researchers check each other's data....
BioCentury | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Head and neck cancer; esophageal cancer Retinoid X receptor (RXR); retinoic acid receptor-g (RARG) In vitro and mouse studies suggest combining RXR and RARG agonists...
BioCentury | Apr 24, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Publication and contact information Endocrine/metabolic disease Obesity Iroquois homeobox 3 (IRX3) In vitro and mouse studies suggest decreasing IRX3...
...and obesity associated (Fto) gene bound the Irx3 promoter and enhanced Irx3 expression. In mice, Irx3...
...were associated with increased IRX3 expression. Next steps could include identifying pharmacological compounds that downregulate IRX3...
BioCentury | Dec 12, 2013
Distillery Therapeutics

Indication: Hematology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Myeloproliferative disorder Retinoic acid receptor (RAR) Mouse studies suggest RAR antagonists could help treat myelofibrosis. Mice with genetic mutations in the...
Items per page:
1 - 10 of 25